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INTRODUCTION

70
Ewing sarcoma (ES) is an aggressive sarcoma of bone and soft tissue that represents 3% of all 136 Five minutes prior to euthanasia, tumor-bearing mice were injected via tail vein with 100µL 137 VectorLab) or high molecular weight FITC-Dextran (2,000,000 mol 138 weight, 10mg/mL in PBS pH 7.4; Sigma-Aldrich).
139
Frozen tumor sections were stained with the following primary antibodies: rat anti-CD31 (1:50, 140 BD Pharmingen), rabbit anti-alpha-smooth muscle actin (α-SMA, 1:100, Abcam Ab5694;), rabbit anti-141 NG2 Chondroitin Sulfate Proteoglycan (NG2, 1:100, AB5320 Millipore), mouse rat anti-Vascular 142 Endothelial cadherin (Ve-caderin, 1:100, BD Pharmingen). Nuclei were stained with Fluoro-Gel II with 143 DAPI (Electron Microscopy Sciences). Images were captured with a Leica DM5500 B upright 144 microscope imaging system (Leica Microsystems) and analyzed using NIS-Elements Imaging Software.
145
For all immunostaining assays, 5 random fields from each tumor sample were quantified as previously 146 described 11 . Images for VE-cadherin and CD31 staining were obtained with a 63x oil immersion 
174
All data and detailed methods will be made available upon reasonable request.
175
7 RESULTS 177 S1PR1 activation by SEW2871 promotes tumor vascular normalization.
178
To determine the effect of S1PR1 activation in ES, A673 subcutaneous and orthotopic 179 xenografts were established in nude mice. Mice were treated with an S1PR1 selective agonist,
180
SEW2871, alone or in combination with doxorubicin. There were no significant differences in 181 microvessel density or total vessel count between tumors in different treatment groups in either 182 subcutaneous or orthotopic tumors (data not shown). In both models, S1PR1 activation promoted tumor 
192
Tumor vascular permeability was assessed by injection of high molecular weight FITC-dextran 193 (2000 KDa), a molecule that does not leak from functional vessels 12 . S1PR1 activation caused a 34% 194 reduction in vascular leakiness of subcutaneous tumor vessels that became more evident in 195 doxorubicin-treated mice (87%; DOXOxSEW p=0.005, Fig. 1G ). In the orthotopic model, a significant 196 reduction in dextran leakage was observed in both tumors treated with SEW2871 alone (53%) or in 197 combination with doxorubicin (52%; SEW p=0.004, Fig. 1G ).
198
To confirm improvement in barrier integrity by the S1PR1 activation, we analyzed VE-cadherin 
204
To study the impact of S1PR2 inhibition on tumor angiogenesis, mice bearing subcutaneous 205 A673 tumors were treated with JTE-013, doxorubicin, or the combination of JTE-013 and doxorubicin.
206
Inhibition of S1PR2 caused a significantly higher microvessel density (p=0.027) that appeared more 207 elongated (p=0.068) with a greater number of open lumens (p=0.067) in subcutaneous tumors ( Fig. 2A , 208 C). There was no significant effect of JTE-013 in remodeling microvessel structure and organization in 209 orthotopic tumors (data not shown). Although a-SMA ( Fig. 2A , D) and NG2 cell coverage did not 210 change ( Fig. 2A, E) , JTE-013 reduced tumor vessel leakage by 68% and 43.7% in subcutaneous and 211 orthotopic tumors, respectively (p=0.038, Fig. 2F and 2G). Additionally, while the pharmacological 212 inhibition of the S1PR2 pathway did not affect VE-cadherin translocation at the plasma membrane (data 213 not shown), we observed a trend toward S1PR2 antagonism increasing VE-cadherin protein expression 215 216 S1PR1 activation or S1PR2 inhibition improved chemotherapy efficacy.
217
The vascular remodeling observed after SEW2871 treatment correlated with a 2-fold increase 
227
Unlike S1PR1 activation, S1PR2 pathway inhibition did not significantly change CaIX, GLUT-1,
228
HIF1-a, VEGF-A mRNA levels in orthotopic tumors (Fig. 3E ). Still, tumors treated with the combination 9 of JTE-013 and doxorubicin were significantly smaller than tumors treated with doxorubicin alone in 230 both xenograft models (subcutaneous: 43.9%, DOX+JTE vs JTE p=0.02; orthotopic 49.8% better, 231 p=0.03) ( Fig. 3F ). JTE-013 treatment did not enhance the cytotoxicity of doxorubicin in A673 cells in 232 vitro (Fig. 3G ).
234
DISCUSSION
235
Here, we provide evidence that modulating the ratio of S1PR1:S1PR2, by inhibiting S1PR1 or 236 activating S1PR2, may be a novel method to remodel tumor vasculature and increase the delivery and 237 thus the efficacy of chemotherapy.
238
In ES tumors, the activation of S1PR1 preferentially manifested as more elongated and open 239 lumen vessels markedly covered with mural cells. Instead of promoting vascular sprouting and 240 neoformation as previously reported in PyMT breast cancer 13 , the activation of S1PR1 by the agonist 241 SEW2871 principally remodeled the morphology of ES tumor vessels to a more mature phenotype.
242
This different vascular response may be partially dependent on tumor type. In comparison to other 243 tumor types, ES vascular network is unique as it is characterized by a more morphologically organized 244 vascular network 10 . However, consistent with other tumors, vasculature is dysfunctional and hyper-245 permeable.
246
The inhibition of S1PR2 by the antagonist JTE-013 only marginally increased the microvessel 247 density, consistent with a previous report in S1PR2 -/mice bearing Lewis Lung carcinoma and 248 B16BL6 14 . Since more significant effects on vascular remodeling was observed by activating S1PR1, 249 the inhibition of S1PR2 by pharmacological modulation might be not sufficient enough to overcome the 250 vascular dysfunction largely caused by lack of S1PR1 pathway activations in ES tumors.
251
In addition, we demonstrated that improved endothelial cells junction function might be involved 252 in tumor vascular normalization. Activation of S1PR1 reduced leakage of tumor vessels by stimulating 253 the recruitment of mural cells around the endothelium and increasing VE-cadherin localization at 254 endothelial junctions. Inhibition of S1PR2 also decreased vascular hyper-permeability, but the 255 mechanism by which this occurs is less clear, as changes to VE-cadherin localization were subtle. The 10 trend toward increased VE-cadherin expression after inhibition of S1PR2 is consistent with previous 257 reports that S1PR2 signaling via NF-κB 15 promotes the expression of the zinc-finger transcription factor 258 Snail that represses VE-cadherin transcription in endothelial cells exposed to cancer cell-conditioned 259 media 16, 17 .
260
In addition, we demonstrated that the S1PR1 agonism by SEW2871 contributes to increased 261 blood vessel perfusion and oxygenation of the tumor. Lower levels of hypoxia responsive transcripts,
262
including VEGFa, confirm a reduction in hypoxia 18 . Considering that lower levels of VEGFa result in 263 more stable endothelial cell adhesion junctions 5,19 , S1PR1 activation may alternatively increase vessel 264 function as a result of decreased tumor hypoxia.
265
Moreover, since hypoxia induces cellular adaptations that promote cell survival and resistance 266 to chemotherapy 20 , the reduced hypoxic environment likely contributes to a greater anti-tumor 267 response. By using athymic nude mice, which lack functional T-cells, we removed any possible effects 268 of S1P receptor signaling modulation on lymphocytes trafficking and immune regulation 21 . Therefore,
269
the increased chemotherapy efficacy observed by the combined therapy was likely endothelial cell 270 dependent.
271
Our findings demonstrate that S1PR1 and S1PR2 in ES vasculature can be modulated to 272 normalize tumor vessels and improve chemotherapy efficacy. As such, the pharmacologic targeting of 273 S1PR1 and S1PR2 warrants further study as potential adjuvant therapy targets for Ewing sarcoma 274 patients. 
